Expertise in
3
conditions

Liyun Y. Miao

No. 321 Zhongshan Road, 
Nanjing, CN 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
3
conditions
No. 321 Zhongshan Road, 
Nanjing, CN 

Overview

Liyun Miao practices practicing medicine in Nanjing, China.

Miao is highly rated in 3 conditions, according to our data. Their clinical expertise encompasses Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), EGFR Positive Lung Cancer, and NUT Carcinoma.

They are actively involved in clinical research, co-authoring 79 peer reviewed articles and participating in 2 clinical trials.

Locations

No. 321 Zhongshan Road, Nanjing, 210008, China
Other Locations
321 Zhongshan Road, Nanjing, 210008, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1)
A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1)
Enrollment Status: Recruiting
Publish Date: May 27, 2026
Intervention Type: Drug
Study Drug: Repotrectinib
Study Phase: Phase 1/Phase 2
LIBRETTO-431: A Multicenter, Randomized, Open-Label, Phase 3 Trial Comparing Selpercatinib to Platinum-Based and Pemetrexed Therapy With or Without Pembrolizumab as Initial Treatment of Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer
LIBRETTO-431: A Multicenter, Randomized, Open-Label, Phase 3 Trial Comparing Selpercatinib to Platinum-Based and Pemetrexed Therapy With or Without Pembrolizumab as Initial Treatment of Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer
Enrollment Status: Active_not_recruiting
Publish Date: October 21, 2025
Intervention Type: Drug
Study Drugs: Selpercatinib, Carboplatin, Cisplatin, Pemetrexed, Pembrolizumab
Study Phase: Phase 3
View 1 Less Clinical Trial

79 Total Publications

Ensartinib in Resected ALK-Positive Non-Small-Cell Lung Cancer.
Ensartinib in Resected ALK-Positive Non-Small-Cell Lung Cancer.
Journal: The New England journal of medicine
Published: July 08, 2026

Frequently Asked Questions about Liyun Y. Miao

Is Liyun Y. Miao a top-rated expert for Lung Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Liyun Y. Miao is classified as an Advanced expert for Lung Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Liyun Y. Miao participate in research or clinical trials?

Yes. Liyun Y. Miao has published 79 articles and abstracts on conditions like Lung Cancer. You can view a list of Liyun Y. Miao's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Miao's expertise for a condition
ConditionClose
      View All 14 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile